Based on the strong correlation between the NES and drug response at single‐cell resolution, scPharm successfully identified the sensitive subpopulations in ER‐positive and HER2‐positive human breast cancer tissues, revealed dynamic changes in the resistant subpopulation of human PC9 cells treated with erlotinib, and expanded its ability to a mouse model. The gene discussed is ERBB2; the disease is breast cancer.